Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study

Fig. 3

Survival curves of patients with HER2-positive GC evaluated in the phase Ib and phase II studies. Kaplan–Meier plot of PFS for different treatment lines (a) and PD-L1 statuses (b). Kaplan–Meier plot of OS for different treatment lines (c) and PD-L1 statuses (d)

Back to article page